A genetic analysis of more than 13,500 participants published on September 29 indicates that low-dose aspirin is associated with a 70 percent lower relative risk of dementia among older adults with a specific genetic profile. Conducted by researchers at Monash University using data from the ASPREE Trial (Aspirin in Reducing Events in the Elderly), the study points toward a potential shift away from universal preventative treatments toward genetically tailored medicine.
Genetic Markers and Dementia Risk Reduction
Researchers examined whether specific genetic factors influenced how aspirin impacts dementia risk in older populations. According to findings published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, participants scoring in the highest 20 percent for a genetic marker linked to platelet count experienced distinct outcomes depending on their treatment group. Among those in this genetic subgroup, 1 percent of participants taking aspirin developed dementia, compared to 3.3 percent of those who received a placebo. This disparity translates to an approximately 70 percent reduction in relative risk for the treated group.
Bleeding Risks Associated with Aspirin Therapy
Despite the observed decrease in dementia risk, the trial revealed significant safety trade-offs for participants with this specific genetic makeup. Major bleeding events occurred more frequently among those assigned to the aspirin regimen. Specifically, 4.4 percent of participants taking aspirin experienced major bleeding, compared to 2.1 percent of participants taking the placebo.
Lead author Peter Fransquet, a research fellow at Monash’s School of Public Health and Preventive Medicine, stated that the findings suggest genetics could eventually help clinicians identify specific patient populations that may benefit from targeted preventive treatment, moving away from a uniform medical approach.
Next Steps for Clinical Research
Monash University researchers emphasized that these observational genetic findings require substantial follow-up validation. The association must be confirmed through independent observational studies and tested specifically within a randomized clinical trial designed explicitly for individuals carrying the targeted genetic profile. Investigators cautioned the public against starting low-dose aspirin regimens for dementia prevention based on this study alone, urging patients to consult healthcare providers before making any changes to their medication routines.
Worth a look